Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ: LEXXW )

0.2010 UNCHANGED
Streaming Delayed Price Updated: 3:57 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 Next >
Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences 1st-Ever Study Evaluating DehydraTECH-CBD’s Effect on Diabetes
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes
Via ACCESSWIRE
Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study
Via ACCESSWIRE
Lexaria's Human Clinical Hypertension Study a Success
Via ACCESSWIRE
Lexaria Discusses Valuation Metrics for Biotech Industry
Via ACCESSWIRE
Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields Remarkable Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors
Via ACCESSWIRE
Lexaria Receives New Patent in Mexico
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Positive FDA Feedback Concerning Opening IND Program
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-CBD Hypertension Study Completes Dosing with No Serious Adverse Events
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's DehydraTECH CBD Hypertension Study Dosing Complete With No Serious Adverse Events
Lexaria Bioscience Corp. (NASDAQ: LEXX) (NASDAQ: LEXXW) revealed that dosing with Lexaria's DehydraTECH-processed CBD has been completed in its multi-week human clinical hypertension study HYPER-H21-4 
Via Benzinga
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
KELOWNA, BC / ACCESSWIRE / July 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
Exposures Product Safety
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Licensee Launches Ko Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
Via ACCESSWIRE
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
KELOWNA, BC / ACCESSWIRE / July 26, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Supply Chain
Exposures Supply Chain
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
KELOWNA, BC / ACCESSWIRE / July 14, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Nearing Start Date for Its Human Nicotine Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria's Human Nicotine Study Nearing Start Date
Lexaria is targeting the oral nicotine pouch category, one of the fastest growing segments of the nicotine industry. 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH
KELOWNA, BC / ACCESSWIRE / July 7, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that... 
From Lexaria Bioscience Corp.
Via AccessWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Enters Strategic Manufacturing, License Agreements with BevNology
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Signs Manufacturing and License Agreements with BevNology
KELOWNA, BC / ACCESSWIRE / June 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Grants License to AnodGen Bioceuticals
KELOWNA, BC / ACCESSWIRE / June 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
KELOWNA, BC / ACCESSWIRE / June 6, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has... 
From Lexaria Bioscience Corp.
Via AccessWire
Exposures Product Safety
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce a... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Grants License to Valcon Medical for the European Market
KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis
Exposures Cannabis
Lexaria Announces 2022 Annual Meeting Results
KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Bioscience (NASDAQ: LEXX) Secures Patent For DehydraTECH To Deliver Antivirals
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.